RIGL Earnings & Financial Statements
Rigel Pharmaceuticals, Inc.
$46.82
-$0.32(-0.68%)
69
Overall
80
Value
63
Tech
65
Quality
Market Cap
$874.59M
Volume
159.95K
52W Range
$24.95 - $52.24
Target Price
$63.00
RIGL earnings and financial statements: Rigel Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
RIGL Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $294.28M | $179.28M | $116.88M | $120.24M | $149.24M |
| Cost of revenue | $19.62M | $18.65M | $7.11M | $1.75M | $1.08M |
| Operating income | $125.47M | $24.19M | -$20.49M | -$55.55M | -$12.50M |
| EBITDA | $131.56M | $28.51M | -$16.98M | -$53.87M | -$11.29M |
| Net income | $367.02M | $17.48M | -$25.09M | -$58.57M | -$17.91M |
| EPS (diluted) | $19.48 | $0.99 | $-1.40 | $-3.40 | $-0.11 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $513.59M | $163.98M | $117.22M | $134.28M | $167.33M |
| Total liabilities | $122.11M | $160.69M | $145.87M | $147.90M | $136.95M |
| Shareholders’ equity | $391.48M | $3.29M | -$28.64M | -$13.62M | $30.37M |
| Cash and equivalents | $40.58M | $56.75M | $32.79M | $24.46M | $18.89M |
| Long-term debt | $22.88M | $52.41M | $52.66M | $40.42M | $20.67M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $75.66M | $31.47M | -$5.74M | -$73.76M | $5.88M |
| Capital expenditure | - | -$262.0K | -$15.00M | -$450.0K | -$627.0K |
| Free cash flow | $75.66M | $31.11M | -$20.74M | -$74.21M | $5.25M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RIGL | $46.82 | -0.7% | 159.95K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Rigel Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW